OPENACT: PHASE 2, OPEN-LABEL STUDY OF SIPULEUCEL-T IN METASTATIC CASTRATE-RESISTANT PROSTATE CANCER (MCRPC)

被引：0
作者：
Corman, J. [1 ]
Dawson, N. [2 ]
Hall, S. [3 ]
Nabhan, C. [4 ]
Ferrari, A. [5 ]
Armstrong, A. J. [6 ]
Murdock, M. I. [7 ]
Stewart, F. [8 ]
Sheikh, N. [9 ]
Petrylak, D. P. [10 ]
机构：
[1] Virginia Mason Med Ctr, Seattle, WA 98101 USA
[2] Georgetown Univ, Washington, WA USA
[3] Mt Sinai Sch Med, New York, NY USA
[4] Advocate Lutheran Gen Hosp, Park Ridge, IL USA
[5] NYU, Ctr Canc, New York, NY USA
[6] Duke Univ, Duke Canc Inst, Durham, NC USA
[7] Murdock Urol Associates, Urol, Greenbelt, MD USA
[8] Dendreon Corp, Biometr, Seattle, WA USA
[9] Dendreon Corp, Clin Immunol, Seattle, WA USA
[10] Columbia Univ, Med Ctr, New York, NY USA
来源：
ANNALS OF ONCOLOGY | 2012年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：311 / 311
页数：1
相关论文
共 50 条
[41]   Updated analysis of a phase II study using sorafenib (S) for metastatic castrate-resistant prostate cancer (mCRPC) [J].
Aragon-Ching, J. B. ;
Jain, L. ;
Draper, D. ;
Gulley, J. L. ;
Arlen, P. M. ;
Wright, J. J. ;
Jones, E. ;
Chen, C. C. ;
Figg, W. D. ;
Dahut, W. L. .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
[42]   Real-world experience with sipuleucel-T (Sip-T) in Asian men with castrate-resistant prostate cancer (CRPC). [J].
Zhang, Jingsong ;
Liu, Ming ;
Pan, Jiahua ;
Wei, Xiao X. ;
Harmon, Matthew ;
Azzolina, John ;
Flanders, Scott .
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[43]   Enzalutamide after abiraterone in patients with metastatic castrate-resistant prostate cancer (mCRPC). [J].
Sandhu, Gurprataap Singh ;
Parikh, Rahul Atul ;
Appleman, Leonard Joseph ;
Friedland, David .
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
[44]   Pembrolizumab (pembro) in heavily pretreated metastatic castrate-resistant prostate cancer (mCRPC). [J].
Moses, Marcus Marie ;
Ledet, Elisa ;
Manogue, Charlotte ;
Lewis, Brian E. ;
Barata, Pedro C. ;
Sartor, A. Oliver ;
Layton, Jodi Lyn .
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
[45]   Metastatic castrate-resistant prostate cancer [J].
Schellhammer, Paul .
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2015, 33 (01) :51-52
[46]   Sipuleucel-T: Autologous Cellular Immunotherapy for Men with Asymptomatic or Minimally Symptomatic Metastatic Castrate Resistant Prostate Cancer [J].
Sims, Robert B. .
JOURNAL OF CANCER, 2011, 2 :357-359
[47]   PEAX: Men with metastatic castrate-resistant prostate cancer (mCRPC) treated with either sipuleucel-T (SIP-T), enzalutamide (ENZA) or abiraterone acetate (ABI) undergoing cardiopulmonary exercise testing (CPET). [J].
Harrison, Michael Roger ;
Khouri, Michel ;
Armstrong, Andrew J. ;
Zhang, Tian ;
McNamara, Megan Ann ;
Anand, Monika ;
Bratt, Ellen ;
Hood, Hillary ;
Coyne, Brian ;
Wu, Yuan ;
Healy, Patrick ;
George, Daniel J. .
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
[48]   Immune response from STRIDE, a randomized, phase 2, open label study of sipuleucel-T (sip-T) with concurrent vs sequential enzalutamide (enz) administration in metastatic castration-resistant prostate cancer (mCRPC). [J].
Quinn, David I. ;
Drake, Charles G. ;
Dreicer, Robert ;
Antonarakis, Emmanuel S. ;
Shore, Neal D. ;
Corman, John M. ;
Concepcion, Raoul S. ;
Pieczonka, Christopher Michael ;
Chang, Nancy N. ;
DeVries, Todd ;
Sheikh, Nadeem A. ;
Petrylak, Daniel Peter .
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[49]   Timing of docetaxel chemotherapy and impact on outcomes in metastatic castrate-resistant prostate cancer (MCRPC). [J].
Thomson, Alastair ;
Pollard, Adam ;
Mark, Frances May .
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
[50]   Olaparib in metastatic castrate-resistant prostate cancer [J].
不详 .
BJU INTERNATIONAL, 2020, 126 (02) :235-235
12345